| September 1 |
'Project Runway' Designer Launches New Online Video Series to Educate About Living with HIV and AIDS and Help Combat HIV Stigma |
| September 1 |
Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of Evista in Romania |
| September 1 |
Neurobiological Technologies Announces Board Approval of Plan of Liquidation and Dissolution |
| September 2 |
BioDelivery Sciences to Consolidate Newark Operations and Bioral Amphotericin B Development at Raleigh Headquarters |
| September 2 |
Bristol-Myers Squibb Completes Acquisition of Medarex, Inc. |
| September 2 |
FDA Advisory Committee Recommends Randomized Trial to Support Proposed Indication for Clolar in Adult AML |
| September 2 |
Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation |
| September 2 |
Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department Of Justice Regarding Past Promotional Practices |
| September 3 |
Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion |
| September 3 |
Akela Pharma announces restructuring |
| September 3 |
Algeta Signs $800 Million (EUR560m) Global Agreement With Bayer for Development and Commercialization of Alpharadin for Bone Metastases |
| September 3 |
BioMS Medical Provides Update on Dirucotide |
| September 3 |
Cornerstone Therapeutics Receives Approval to Acquire Commercial Rights to the Antibiotic Factive |
| September 3 |
Delcath Establishes Queensbury, NY Operations Facility |
| September 3 |
FDA Study Indicates Most Industry Postmarketing Studies Meet Timelines |
| September 3 |
Pfizer, Wyeth and Johnson & Johnson to Present at PharmaMed Marketing & Media Conference |
| September 3 |
Three Directors Set For Newly-Combined Merck |
| September 3 |
Metabasis Hires Financial Advisor to Evaluate Strategic Alternatives |
| September 3 |
Blue Spoon Consulting Updates Briefing Note: ?Pharmaceutical Promotion At Its Productivity Frontier' |
| September 4 |
Elan Issues Statement Regarding Federal Court Ruling on Tysabri Collaboration Agreement |
| September 4 |
Carey & Danis LLC Announces Four Lawsuits Against the Makers of Levaquin |
| September 4 |
Tim Gunn Hosts Addressing Psoriasis Fashion Show to Raise Awareness of Psoriasis |
| September 4 |
Biogen Idec Announces Proposal to Acquire All Outstanding Shares of Facet for $14.50 per Share in Cash |
| September 8 |
Supply Plan of "Tamiflu" Anti-influenza Drug |
| September 8 |
Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government |
| September 8 |
Shire News: Update on velaglucerase alfa |
| September 8 |
Roche Announces New Corporate Executive Committee |
| September 8 |
Facet Biotech's Board of Directors Rejects Biogen Idec's Unsolicited Proposal as Inadequate |
| September 8 |
SEC Charges Seattle-Area Biotech Company With Fraudulently Hyping Stem Cell Breakthrough |
| September 9 |
Mylan Parts Ways with Chief Financial Officer Jolene Varney |
| September 9 |
AIR Health Group Launches, First Analytic Marketing Tool Debuts In Pharma Industry |
| September 9 |
Large Majorities of Public Blame Health Insurers, Drug Industry, Republicans and Business for Problems with Our Current Health Care System |
| September 10 |
Dynavax Reports FDA Removes Clinical Hold on HEPLISAV Phase 3 Hepatitis B Vaccine |
| September 10 |
Merck Updates Status of Clinical Development Programs for Investigational CGRP Receptor Antagonist Treatments for Acute Migraine; MK-3207 Clinical Development Discontinued |
| September 10 |
Marketing Exclusivity for First-in-Class Drugs Has Shortened to 2.5 Years |
| September 11 |
Alkermes Chairman Richard Pops to Resume Role of CEO |
| September 11 |
Mistrial Declared in First Federal Fosamax Trial |
| September 11 |
One-stop SEO Service Provider Delivers New Options to Strengthen Online Businesses |
| September 11 |
HPV Vaccine Study Shows Why Few Women Getting Shots |
| September 11 |
Roger Green and Associates (RG+A) announce DPS Tracker |
| September 11 |
Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued |
| September 14 |
Alcon to Acquire Swiss Biotechnology Firm, ESBATech AG |
| September 14 |
Lilly Names New Business Leaders |
| September 14 |
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients |
| September 15 |
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010 |
| September 15 |
Elan Cures Breach of Tysabri Collaboration Agreement and Amends Terms of Transaction with Johnson & Johnson |
| September 15 |
78 percent of Americans see pharmaceutical industry deals as harmful |
| September 15 |
BioCryst Announces Partnerships for Peramivir for Influenza Outside the U.S. |
| September 15 |
Chicago Interactive Agency Marcel Media Wins HealthLeaders Media Marketing Award |
| September 15 |
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product |
| September 16 |
Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia Tbk |
| September 16 |
Oncologists Visit Pharma Sites and Post Professional Content Online More Frequently than the Average Physician |
| September 17 |
FDA Sends Warning Letters to Allergan and Bioniche |
| September 17 |
FDA Requires Boxed Warning for Promethazine Hydrochloride Injection |
| September 17 |
Wellcome Trust and Merck Launch First of Its Kind Joint Venture to Develop Affordable Vaccines for Low-Income Countries |
| September 17 |
Renovo - End of Offer Period & Restructuring |
| September 17 |
Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment |
| September 17 |
FDA Sends Warning Letter to Bioniche Pharma Over Sotradecol Web Pages |
| September 18 |
Pharmapalooza 2 Keeps the Beat Going Strong for Children's Health |
| September 18 |
ZymoGenetics Appoints Dennis M. Miller, Ph.D., Senior Vice President, Research and Preclinical Development |
| September 18 |
New Appointments at London Genetics to Drive Strategy Forward |
| September 18 |
Rite Aid Names Ernie Richardsen Group Vice President, Pharmaceutical Purchasing and Clinical Services |
| September 21 |
AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation |
| September 21 |
King Announces Commercial Availability of EMBEDA |
| September 21 |
Maxygen Announces Consummation of Joint Venture Transaction With Astellas |
| September 21 |
Biogen Idec Commences Tender Offer for Facet Biotech |
| September 22 |
David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics |
| September 22 |
IMS Appoints Don Otterbein General Manager, Business Transformation Services, to Lead Expanded Knowledge Process Outsourcing Initiative |
| September 22 |
Adolor Acquires Rights to Clinical-Stage Product Candidate from Eli Lilly and Company |
| September 22 |
MedWatch - Natalizumab (marketed as Tysabri) - FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) |
| September 22 |
Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands |
| September 22 |
Appointment of Claude Bertrand as Executive Vice President, Chief Scientific Officer of Ipsen |
| September 22 |
Lilly Announces New U.S. Affiliate Leader |
| September 22 |
Health Industry Lobbyists Hosted at Least 130 Fundraisers for Members of Congressional Health Committees This Year |
| September 22 |
GSW Worldwide Announces New Members |
| September 22 |
ScienceFirst Staff Expansion |
| September 22 |
Mink Named President & CEO of ANGUS Chemical Company |
| September 22 |
Baer Consulting launches new division |
| September 22 |
Burnham Appoints Michael R. Jackson, Ph.D., Vice President for Drug Discovery & Development |
| September 23 |
CombinatoRx Stock Trading Halted Today; FDA Advisory Committees Meet to Discuss Exalgo |
| September 23 |
Janssen-Cilag's Stelara (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis |
| September 23 |
LEO Pharma Repurchases Product Rights From Warner Chilcott |
| September 23 |
Merck and QIAGEN Collaborate to Accelerate Access to Cervical Cancer Vaccination and Screening in Developing Countries |
| September 23 |
AB Research adds CRO veteran Daniel Menard to its management team as Canadian and Hungarian sites's activity climb to historical highs |
| September 23 |
Former FDA Commissioner Joins CHT |
| September 23 |
Semafore Retains Management Consulting Firm; Names Principal to Key Management Position |
| September 23 |
Aegis Adds Vice President of Sales |
| September 23 |
Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development |
| September 23 |
Michael Howe, Former CEO MinuteClinic, Joins MEDNETWorld Board of Directors |
| September 23 |
IGI Labs, Inc. Announces Narendra N. Borkar's Appointment to Its Board of Directors |
| September 23 |
U.S. District Court Upholds Validity of Lilly's Evista Patents Through 2014 |
| September 23 |
ScienceFirst Staff Expansion |
| September 24 |
Sepracor Announces Expiration of Hart-Scott-Rodino Waiting Period |
| September 24 |
Teva Provides Update on Generic Evista Litigation |
| September 24 |
OctoPlus N.V. (NL) - OctoPlus announces further efficiency measures |
| September 25 |
Pfizer and Eisai Continue Aricept Collaboration |
| September 25 |
Tamiflu (oseltamivir) for Oral Suspension: Medication Dosing Errors Reported |
| September 25 |
Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricep |
| September 25 |
Frances D. Fergusson And John P. Mascotte Elected To Pfizer's Board Of Directors |
| September 25 |
Sitagliptin (marketed as Januvia and Janumet): Cases of acute pancreatitis reported |
| September 25 |
Heart Rhthym Society Taps Publicis Consultants |
| September 25 |
Merck Statement About JANUVIA (sitagliptin) and JANUMET (sitagliptin/metformin) |
| September 26 |
Exjade (deferasirox) - Early Communication about risk of adverse reactions in patients with myelodysplastic syndrome |
| September 27 |
Teva Provides Update on Generic Seroquel Litigation |
| September 28 |
Abbott to Acquire Solvay Pharmaceuticals Business |
| September 28 |
Johnson & Johnson and Crucell Announce Strategic Collaboration to Develop Innovative Products, Including Therapies for Influenza Prevention and Treatment |
| September 29 |
ZymoGenetics Filing: Merck Serono Discontinues Atacicept Study |
| September 30 |
Pfizer Receives Approval from China's Ministry of Commerce for Pending Wyeth Acquisition |
| September 30 |
Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes |
| September 30 |
FDA Issues Strategic Plan for Risk Communication |
